{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-133657","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.633467+00:00","generated_at":"2026-06-28T13:51:25.776892+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cognition Therapeutics appoints Ellen Richstone to board; director Breedlove resigns","bullets":["Board increased from six to seven directors; Ellen B. Richstone appointed as Class I director effective Nov 1, 2021.","Richstone will chair the Audit Committee and qualifies as audit committee financial expert under SEC rules.","Received option to purchase 16,670 shares at $12.10 per share, vesting monthly over 36 months.","Director Mark H. Breedlove notified resignation effective Dec 31, 2021; decision not due to any disagreement with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-133657","json":"https://secwatch.observer/filing/0001104659-21-133657.json","markdown":"https://secwatch.observer/filing/0001104659-21-133657.md","text":"https://secwatch.observer/filing/0001104659-21-133657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921133657/0001104659-21-133657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921133657/tm2131759d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:51:25.776892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b143db8c9","claim":"Mark H. Breedlove resigned as Director at COGNITION THERAPEUTICS INC.","evidence_excerpt":"On October 29, 2021, Mark H. Breedlove notified the Board that he intends to resign as a member of the Board, effective December 31, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921133657/0001104659-21-133657-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e3c691edb0","claim":"Ellen B. Richstone was appointed as Class I Director at COGNITION THERAPEUTICS INC.","evidence_excerpt":"Effective November 1, 2021, in connection with the Board Increase, the Board appointed Ellen B. Richstone to serve as a Class I member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465921133657/0001104659-21-133657-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}